By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Genentech 

1 DNA Way

South San Francisco  California  94080-4990  U.S.A.
Phone: 650-225-1000 Fax: 650-225-6000


SEARCH JOBS

Since 2005, Genentech has been expanding its facilities in Oceanside, about 35 miles north of San Diego. Today, the campus spans 60 acres and includes a multi-product, biotech manufacturing and clinical operations complex with six buildings totaling 500,000 square feet. Upon receiving U.S. Food and Drug Administration licensure in 2007, the Oceanside facility added 90,000 liters of capacity that are now approved for the production of Rituxan and Avastin bulk drug substance.

On the Southern California Coast, halfway between Los Angeles and San Diego, Oceanside is a beautiful beachfront community of roughly 200,000 people. As one of Oceanside’s largest employers, Genentech takes great pride in the impact we have on the community, but also in the impact the community has on our employees.

Please view our company video on YouTube:
http://www.youtube.com/genentech#p/u/1/GJH4X5gxxf0

Connect with us via Social Media:

Facebook: www.facebook.com/GenentechJobs

Twitter: www.twitter.com/GenentechJobs

LinkedIn: www.linkedin.com/company/genentech



YEAR FOUNDED:

1976

LEADERSHIP:

CEO: Ian T. Clark

CEO: Ed Harrington

Chief Medical Officer: Sandra J. Horning, MD

Chief Compliance Officer: Frederick C. Kentz, III

CLINICAL TRIAL:

Please click here for clinical trial information.


Key Statistics


Email:
Ownership: Subsidiary

Web Site: Genentech
Employees: 10,000+
Symbol: RHHBY
 



Industry
Biotechnology

Segment
Biotherapeutics





Company News
Exelixis (EXEL) Announces Settlement Of Dispute With Genentech (RHHBY) Regarding Companies’ Collaboration Agreement For Cobimetinib 7/20/2017 10:58:53 AM
Genentech (RHHBY) R&D Exec Reveals Alzheimer's is Still A Priority 7/19/2017 6:53:52 AM
Genentech (RHHBY) Shows Off Phase III Hemophilia A Data 7/10/2017 6:52:23 AM
Comprehensive Study By AstraZeneca PLC (AZN) And Genentech (RHHBY) Confirms Superiority Of Insphero Human Liver Microtissues For Prediction Of Drug-Induced Liver Injury 6/29/2017 7:29:49 AM
Genentech (RHHBY)’s Emicizumab Showed Positive Results In Phase III Studies (HAVEN 1 And HAVEN 2) In Hemophilia A With Inhibitors 6/26/2017 6:38:14 AM
Genentech (RHHBY)'s Hemophilia Blockbuster Contender Hits Phase III Goals, But Questions Remain 6/26/2017 5:44:07 AM
FDA Approves Genentech (RHHBY)'s RITUXAN HYCELA, A Subcutaneous Rituximab Coformulated With Halozyme ENHANZE Technology 6/23/2017 6:25:35 AM
New Data At EAN Show Genentech (RHHBY)’s Ocrevus (Ocrelizumab) Significantly Reduced Multiple Measures Of Disease Progression In Relapsing And Primary Progressive Multiple Sclerosis 6/23/2017 6:03:52 AM
Genentech (RHHBY) Wins No. 1 Top Spot as The Ideal Employer in Life Sciences 6/22/2017 11:27:43 AM
Vital Art And Science Announces License Agreement With Genentech (RHHBY) For Its mVT Service 6/19/2017 9:26:39 AM
12345678910...
//-->